소아용 백신 시장 보고서 : 종류, 기술, 용도, 지역별(2026-2034년)

The global pediatric vaccines market size reached USD 42.4 Billion in 2025 . Looking forward, IMARC Group expects the market to reach USD 75.1 Billion by 2034 , exhibiting a growth rate (CAGR) of 6.35% during 2026-2034 . The growing conduction of vaccination programs, increasing focus on combination vaccines, and rising partnerships between pharmaceutical companies and healthcare organizations for fast-tracking the development and distribution of vaccines are some of the major factors propelling the market.

Pediatric vaccines are medical preparations that stimulate the immune system to recognize and fight specific infectious agents, such as bacteria or viruses. They comprise weakened or inactivated forms of the pathogens, or components of the pathogens, which prompt the immune system to develop a defense mechanism against the targeted disease. They provide protection from measles, polio, pertussis (whooping cough), hepatitis, and influenza. They undergo rigorous testing and evaluation to ensure their safety before being approved for use. They prevent the spread of diseases that can cause severe complications or death in children.

At present, the increasing occurrence of various infectious and potentially life-threatening diseases, such as polio, tuberculosis (TB), and malaria among children, is impelling the growth of the market. Besides this, rising government initiatives around the world aimed at immunizing children against preventable diseases are contributing to the growth of the market. In addition, the growing technological advancements in vaccine storage and distribution methods for improving the supply chain in regions where medical infrastructure may be less developed are offering a favorable market outlook. Apart from this, increasing partnerships between pharmaceutical companies and healthcare organizations for fast-tracking the development and distribution of vaccines are supporting the growth of the market. Additionally, the rising construction of clinics and hospitals around the world to improve healthcare services is bolstering the growth of the market.

PEDIATRIC VACCINES MARKET TRENDS/DRIVERS:

Growing conduction of vaccination programs

The increasing implementation of vaccination programs is notably bolstering the pediatric vaccines market. These vaccination initiatives, supported by governmental and non-governmental organizations, play a pivotal role in safeguarding the health and well-being of children. As more children receive essential immunizations against various diseases, the demand for pediatric vaccines experiences a proportional rise. Besides this, vaccination programs, with their focus on disease prevention, are decreasing the incidence of targeted illnesses among children. This subsequently translates into a reduced burden on healthcare systems and families, thereby enhancing the overall quality of life for children and their caregivers. Furthermore, the growing awareness among parents and healthcare providers about the importance of immunizations is rising the vaccine uptake rates.

Increasing focus on combination vaccines

The heightened emphasis on combination vaccines is contributing to the positive evolution of the pediatric vaccines market. Combination vaccines offer a strategic approach to immunization by providing protection against multiple diseases in a single formulation. This approach simplifies the vaccination process for healthcare providers, caregivers, and children alike, resulting in improved compliance and vaccine coverage rates. Moreover, combination vaccines address the challenges of vaccine hesitancy and the possibility of missed doses. As children receive protection against multiple diseases with one injection, the perceived burden of vaccinations is significantly reduced. This encourages parents to adhere to recommended vaccination schedules and contributes to achieving higher rates of full immunization coverage.

Rising development of novel vaccines

The increasing development of novel vaccines is playing a pivotal role in driving positive growth within the pediatric vaccines market. The emergence of new vaccines tailored specifically for the health needs of children contributes to enhanced disease prevention, improved public health outcomes, and expanded market opportunities. The development of novel vaccines also reflects advancements in vaccine technology and research. Cutting-edge research methodologies, such as genomics and bioinformatics, enable scientists to identify potential vaccine candidates more rapidly and accurately. This accelerated pace of discovery is creating vaccines that are efficacious and align with the evolving epidemiological landscape. Furthermore, the rising development of novel vaccines is stimulating collaboration between public health organizations, research institutions, and vaccine manufacturers. These partnerships facilitate the timely introduction of new vaccines and ensure their efficient distribution to the pediatric population.

PEDIATRIC VACCINES INDUSTRY SEGMENTATION:

Breakup by Type:

• Multivalent
• Monovalent

Multivalent dominates the market

Multivalent pediatric vaccines refer to immunization formulations that provide protection against multiple diseases through a single vaccine injection. These vaccines are designed to target two or more different disease-causing agents, such as viruses or bacteria, in a single formulation. Multivalent pediatric vaccines streamline the vaccination process by offering protection against multiple diseases with a single injection. This eliminates the need for multiple shots, reducing discomfort for children and simplifying the vaccination schedule for healthcare providers and caregivers. Multivalent pediatric vaccines optimize healthcare resources by combining multiple vaccines into a single formulation. This can result in cost savings for healthcare systems and reduce the logistical challenges associated with administering separate vaccines.

Breakup by Technology:

• Conjugate
• Live Attenuated
• Inactivated
• Subunit
• Toxoid
• Others

Conjugate holds the largest share in the market

Conjugate vaccines are a type of immunization that enhances the immune response against certain bacteria that have a protective polysaccharide outer coating. These vaccines work by linking or conjugating the bacterial polysaccharides to a carrier protein, creating a complex that stimulates a stronger and more effective immune response, especially in young children whose immune systems might not respond well to polysaccharides alone. Conjugate vaccines not only protect vaccinated individuals but can also reduce the carriage of bacteria in the population. This indirectly limits the spread of bacteria among both vaccinated and unvaccinated individuals. Conjugate vaccines contribute to herd immunity, which is essential for the prevention of the spreading of various infectious diseases among unvaccinated individuals.

Breakup by Application:

• Infectious Disease
• Cancer
• Allergy
• Others

Pediatric vaccines play a crucial role in preventing infectious diseases among children. By providing immunity against harmful pathogens, vaccines contribute to the health and well-being of children and infants. These vaccines are carefully developed based on scientific examination and clinical trials to ensure their safety and effectiveness.

Pediatric vaccines for cancer aim to prevent certain types of cancers that primarily affect children. They target certain infections, such as human papillomavirus (HPV) and hepatitis B virus (HBV) and are known to increase the risk of developing cancer. Besides this, administering vaccines during childhood allows for early prevention of cancer-related infections. This early intervention aligns with a proactive health approach, reducing the risk of cancer development later in life.

Pediatric vaccines play a crucial role in preventing a range of allergies among children. By bolstering the response of the immune system, vaccines help mitigate the risk of developing allergies to common allergens like pollen, dust, and pet dander.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest pediatric vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share since the region due to the rising investment in research operations for the development of various novel vaccines for the prevention of infectious and chronic diseases. Besides this, the increasing awareness among parents and caregivers about the importance of immunization is propelling the growth of the market. Apart from this, rising improvements in the healthcare infrastructure to provide quality treatment and other healthcare facilities to individuals are supporting the growth of the market.

Asia Pacific is estimated to expand further in this domain due to the increasing occurrence of infectious diseases caused by various novel viruses. Besides this, rising initiatives taken by governing agencies and regulatory bodies to promote the significance of vaccination in children are bolstering the growth of the market.

COMPETITIVE LANDSCAPE:

Key market players are diligently focused on enhancing their business strategies by consistently investing in research operations to formulate innovative vaccines that cater to evolving healthcare needs. They are fostering collaborations with research institutions and regulatory bodies to ensure the safety and efficacy of their products. Leading companies are strengthening their supply chain management and distribution networks to ensure timely availability of vaccines. Furthermore, top industry players are actively engaging in educational initiatives to increase awareness about the importance of vaccination, fostering trust and credibility within the community. This concerted effort to innovate, collaborate, and educate showcases their commitment to advancing the field of pediatric vaccines and contributing to public health on a global scale.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Bio-Med (P) Limited
• Daiichi Sankyo Company Limited
• GSK plc
• Indian Immunologicals Limited
• Merck & Co. Inc.
• Panacea Biotec
• Pfizer Inc.
• Sanofi

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global pediatric vaccines market in 2025?

2. What is the expected growth rate of the global pediatric vaccines market during 2026-2034?

3. What are the key factors driving the global pediatric vaccines market?

4. What has been the impact of COVID-19 on the global pediatric vaccines market?

5. What is the breakup of the global pediatric vaccines market based on the type?

6. What is the breakup of the global pediatric vaccines market based on the technology?

7. What are the key regions in the global pediatric vaccines market?

8. Who are the key players/companies in the global pediatric vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Pediatric Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Multivalent
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Monovalent
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Conjugate
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Live Attenuated
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Inactivated
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Subunit
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Toxoid
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Application

• 8.1 Infectious Disease
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cancer
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Allergy
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Bio-Med (P) Limited
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Daiichi Sankyo Company Limited
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 GSK plc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Indian Immunologicals Limited
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Merck & Co. Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Panacea Biotec
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Pfizer Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Sanofi
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis